Korean J Anesthesiol.  2006 Mar;50(3):361-364. 10.4097/kjae.2006.50.3.361.

The Trial of Continuous Intravenous Infusion of Magnesium in Patients with Postherpetic Neuralgia Refractory in Conventional Treatment: A report of 2 cases

• Cheong YK
• Kim TY
• Lee JH

• KMID: 1936743
• DOI: http://doi.org/10.4097/kjae.2006.50.3.361

Abstract

Postherpetic neuralgia is one of the most troublesome diseases in pain clinics. The N-methyl-D-aspartate (NMDA) receptor antagonist, magnesium, reduces the level of neuropathic pain and hyperalgesia in patients with postherpetic neuralgia. Magnesium has been shown to exert a physiological block of the ion channel on the NMDA receptor, thereby preventing extracellular calcium ions from entering the cell and contributing to secondary neuronal changes. Accordingly, we attempted to administer a continuous intravenous infusion of magnesium, which resulted in a decrease in the VAS without side effects.

Keyword

magnesium; neuropathic pain; NMDA receptor antagonist; postherpetic neuralgia

MeSH Terms

Calcium
Humans
Hyperalgesia
Infusions, Intravenous*
Ion Channels
Ions
Magnesium*
N-Methylaspartate
Neuralgia
Neuralgia, Postherpetic*
Neurons
Pain Clinics
Calcium
Ion Channels
Ions
Magnesium
N-Methylaspartate